Who should receive combination therapy for ER positive breast cancer?

Positive lessons of negative trials

Drug repurposing of propranolol

ESMO 2016 conference highlights

Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody:

LUME study of nintedanib finds improved PFS, but no overall survival boost

Left versus right sided GI tumour response in the CRYSTAL trial

Oncolytic virotherapy using coxsackie virus

Results of the Activ8 trial of novel immunotherapy motolimod

Lurbinectedin in PARP resistant breast cancer

Lurbinectedin in BRCA 1/2 breast cancer